Sanofi Tops Pfizer as Number One for Global Pharma Sales
1 (ots/PRNewswire)
EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Sanofi is expected to take the top spot amongst the world's pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biotechnology specialist Genzyme predicted to help win its number one ranking.
"The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years," commented Dr Jonathan de Pass, chief executive of EvaluatePharma. "Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest."
For more in-depth analysis and commentary on this news please visit EP Vantage: http://bit.ly/uY5fYm.
World's Top 15 Pharma Companies
Rx & OTC pharma sales
Market Rank ($bn)
Annual
growth
2011 2012 2014 2016 2011 2012 2014 2016 2011-16
Sanofi 3 1 1 1 47.9 51.6 55.4 58.4 4%
Novartis 2 2 2 2 49.5 49.9 52.2 54.8 2%
Pfizer 1 3 3 3 54.1 49.8 49.7 51.9 (1%)
GlaxoSmithKline 5 6 5 4 39.3 41.2 45.6 50.9 5%
Roche 6 4 4 5 39.1 44.1 46.3 49.0 5%
Merck & Co 4 5 6 6 42.1 41.9 41.4 43.4 1%
Johnson &
Johnson 8 8 7 7 24.8 26.5 29.4 31.5 5%
AstraZeneca 7 7 8 8 32.0 29.2 27.5 25.7 (4%)
Teva 12 10 10 9 17.4 20.3 22.5 24.4 7%
Abbott
Laboratories 9 9 9 10 22.5 23.5 23.7 24.3 2%
Bayer 11 12 11 11 18.9 19.7 21.7 23.4 4%
Takeda 14 13 12 12 17.0 18.2 18.7 20.2 3%
Bristol-Myers
Squibb 13 16 17 13 17.1 14.2 15.4 18.9 2%
Novo Nordisk 17 17 15 14 12.3 13.6 16.4 18.9 9%
Eli Lilly 10 11 14 15 21.5 20.1 17.6 17.9 (4%)About EvaluatePharma Ltd.
The research company EvaluatePharma Ltd was the first to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product sales forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A activity. Launched in 2007, EvaluatePharma(R) Alpha offers a Net Present Value (NPV) valuation service quantifying market events and the impact on product, portfolio and company valuation including the daily online news service EP Vantage(R).
EvaluatePharma(R), EvaluatePharma(R) Alpha, and EP Vantage(R) are services of EvaluatePharma Ltd, headquartered in London, England. In North America, EvaluatePharma Ltd is represented by EvaluatePharma USA, Inc.
Media Contacts: Andrew Beaven Marketing Director, EvaluatePharma Ltd Tel: +44(0)20-7539-1818 Email: andrewb@evaluatepharma.com EvaluatePharma Ltd 11-29 Fashion Street London E1 6PX United Kingdom
Contact:
.